278 related articles for article (PubMed ID: 26188791)
41. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
42. Breast cancer in very young women.
Liukkonen S; Leidenius M; Saarto T; Sjöström-Mattson J
Eur J Surg Oncol; 2011 Dec; 37(12):1030-7. PubMed ID: 21937191
[TBL] [Abstract][Full Text] [Related]
43. Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy.
Min SY; Lee SJ; Shin KH; Park IH; Jung SY; Lee KS; Ro J; Lee S; Kim SW; Kim TH; Kang HS; Cho KH
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e697-705. PubMed ID: 21129858
[TBL] [Abstract][Full Text] [Related]
44. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
45. [Local recurrence based on size after conservative surgery in breast cancer stage T1-T2. A population-based study].
Martínez-Ramos D; Fortea-Sanchis C; Escrig-Sos J; Prats-de Puig M; Queralt-Martín R; Salvador-Sanchis JL
Cir Cir; 2014; 82(3):252-61. PubMed ID: 25238466
[TBL] [Abstract][Full Text] [Related]
46. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
47. Prognostic factors affecting disease-free survival in patients at age 35 or younger with invasive breast cancer.
Koca B; Kuru B; Karabicak I; Yürüker SS; Ozen N
Ann Ital Chir; 2014; 85(3):249-53. PubMed ID: 25074433
[TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of nodal involvement region in clinical stage IIIc breast cancer patients who received primary systemic treatment, surgery, and radiotherapy.
Noh JM; Kim KH; Park W; Suh CO; Huh SJ; Choi DH; Keum KC; Kim YB
Breast; 2015 Oct; 24(5):637-41. PubMed ID: 26283599
[TBL] [Abstract][Full Text] [Related]
49. Prevention of locoregional recurrence and distant metastasis in Japanese breast cancer patients using Japanese standard postoperative radiation fields: Experience at a single institution.
Takuwa H; Tsuji W; Yotsumoto F; Yamauchi C
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1191. PubMed ID: 32721113
[TBL] [Abstract][Full Text] [Related]
50. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
51. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: a nationwide retrospective study.
Sohn G; Son BH; Lee SJ; Kang EY; Jung SH; Cho SH; Baek S; Lee YR; Kim HJ; Ko BS; Yu ; Lee JW; Ahn SH
J Surg Oncol; 2014 Sep; 110(3):270-4. PubMed ID: 24863883
[TBL] [Abstract][Full Text] [Related]
52. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
Garg AK; Strom EA; McNeese MD; Buzdar AU; Hortobagyi GN; Kuerer HM; Perkins GH; Singletary SE; Hunt KK; Sahin A; Schechter N; Valero V; Tucker SL; Buchholz TA
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):138-45. PubMed ID: 15093909
[TBL] [Abstract][Full Text] [Related]
53. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
[TBL] [Abstract][Full Text] [Related]
54. Limited Supraclavicular Radiation Field in Breast Cancer With ≥ 10 Positive Axillary Lymph Nodes.
Yu JI; Park W; Choi DH; Huh SJ; Nam SJ; Kim SW; Lee JE; Kil WH; Im YH; Ahn JS; Park YH; Cho EY
Clin Breast Cancer; 2016 Jun; 16(3):e15-21. PubMed ID: 26732519
[TBL] [Abstract][Full Text] [Related]
55. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
56. Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery.
Gosset M; Hamy AS; Mallon P; Delomenie M; Mouttet D; Pierga JY; Lae M; Fourquet A; Rouzier R; Reyal F; Feron JG
PLoS One; 2016; 11(8):e0159888. PubMed ID: 27494111
[TBL] [Abstract][Full Text] [Related]
57. Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy.
Bijker N; Rutgers EJ; Peterse JL; van Dongen JA; Hart AA; Borger JH; Kroon BB
Cancer; 1999 Apr; 85(8):1773-81. PubMed ID: 10223572
[TBL] [Abstract][Full Text] [Related]
58. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
59. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
60. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
